[SCHEDULE 13D/A] CAMP4 Therapeutics Corporation SEC Filing

Rhea-AI Filing Summary

Camp4 Therapeutics amended a Schedule 13D to report participation by Polaris-related investors in a private placement and updated beneficial ownership figures. PP VII and PEF VII purchased 1,221,721 and 85,468 shares, respectively, at $1.53 per share on September 11, 2025, for aggregate amounts of $1,869,233.13 and $130,766.04.

The Purchase Agreement contemplates an Initial Closing issuing 26,681,053 shares and pre-funded warrants for 6,003,758 shares at $1.53 per share (pre-funded warrants at $1.5299). Management subscribed for additional small tranches at $1.65 per share, producing approximately $50.1 million of gross proceeds at the Initial Closing before fees. A Second Closing could issue up to 32,721,172 more shares/pre-funded warrants if a CTA milestone is met and either a $7.50 VWAP threshold is achieved or investors holding a majority waive the price condition. A Registration Rights Agreement obligates the issuer to register the resale of the issued shares and underlying warrant shares.

Positive

• Immediate capital raised: Approximate gross proceeds of $50.1 million at the Initial Closing before fees
• Investor commitment: Significant issuance and investor participation via the Purchase Agreement and pre-funded warrants indicate financing support
• Registration rights: A Registration Rights Agreement obligates the issuer to register resale of the issued shares and warrant shares, improving liquidity for investors

Negative

• Potential dilution: The Second Closing could issue up to 32,721,172 additional shares or pre-funded warrants, materially increasing outstanding shares
• High price hurdle: Automatic Second Closing requires a VWAP of $7.50, which may limit immediate additional financing absent investor waivers
• Concentrated shared voting power: Board-affiliated parties (including Amir Nashat) are disclosed as sharing voting and dispositive power over multiple pooled holdings, representing potential control concentration

Insights

Financial Analyst

TL;DR: Private placement raises immediate capital but creates potential dilution; second closing is milestone- and price-dependent.

The Initial Closing supplies near-term financing of roughly $50.1 million in gross proceeds and shows investor support at $1.53 per share with some management participation at $1.65. The conditional Second Closing could substantially increase share count by up to 32.7 million shares or equivalent pre-funded warrants, which is material relative to the reported 46.9 million share pro forma base used to calculate percentages. The $7.50 VWAP hurdle materially limits automatic dilution from the Second Closing absent investor waiver. These are capital-raising and dilution mechanics; no earnings or operational performance metrics are provided in this amendment.

Corporate Governance Expert

TL;DR: Board-affiliated investors hold meaningful shared voting power; registration rights and investor agreements shape resale and control dynamics.

The filing discloses that managing members and a director (Amir Nashat) may be deemed to share voting and dispositive power across several Polaris entities, with Nashat-associated holdings totaling 3,932,251 shares (8.4% of the class on the pro forma base). The Purchase Agreement and Registration Rights Agreement create contractual obligations that affect future liquidity and shareholder composition. The right of investors to waive the price threshold for the Second Closing centralizes significant decision authority among participating investors and could change ownership concentration depending on waivers exercised.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Camp4 Therapeutics Corporation

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

13463J101

(CUSIP Number)

Lauren Crockett
Polaris Partners, One Marina Park Drive, 8th Floor
Boston, MA, 02210
(781) 290-0770

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/09/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Polaris Management Co. VII, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,023,161.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,023,161.00

11

Aggregate amount beneficially owned by each reporting person

3,023,161.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.4 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Consists of (i) 2,825,500 shares of Common Stock (as defined in Item 1 of the Original Schedule 13D (as defined below)) held of record by PP VII (as defined in Item 2(a) of the Original Schedule 13D) and (ii) 197,661 shares of Common Stock held of record by PEF VII (as defined in Item 2(a) of the Original Schedule 13D). PMC VII (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of each of PP VII and PEF VII and may be deemed to have voting, investment and dispositive power with respect to these securities. The PMC VII Managing Members (as defined in Item 2(a) of the Original Schedule 13D), including Mr. Nashat (as defined in Item 2(a) of the Original Schedule 13D) who is a member of the Issuer's board of directors, are the managing members of PMC VII and may be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 46,878,487 shares of Common Stock, which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter-ended June 30, 2025, filed with the Securities and Exchange Commission (the "Commission") on August 14, 2025 (the "Form 10-Q") plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in a private placement (the "Private Placement"), as reported by the Issuer in its Current Report on Form 8-K, filed with the Commission on September 10, 2025 (the "Form 8-K").

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Polaris Partners VII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,825,500.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,825,500.00

11

Aggregate amount beneficially owned by each reporting person

2,825,500.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.0 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All shares of Common Stock are held of record by PP VII. PMC VII is the general partner of PP VII and may be deemed to have voting, investment and dispositive power with respect to these securities. The PMC VII Managing Members, including Mr. Nashat who is a member of the Issuer's board of directors, are the managing members of PMC VII and may be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 46,878,487 shares of Common Stock, which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as set forth in the Form 10-Q plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in the Private Placement, as set forth in the Form 8-K.

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Polaris Entrepreneurs' Fund VII, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 197,661.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 197,661.00

11

Aggregate amount beneficially owned by each reporting person

197,661.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All shares of Common Stock are held of record by PEF VII. PMC VII is the general partner of PEF VII and may be deemed to have voting, investment and dispositive power with respect to these securities. The PMC VII Managing Members, including Mr. Nashat who is a member of the Issuer's board of directors, are the managing members of PMC VII and may be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 46,878,487 shares of Common Stock, which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as set forth in the Form 10-Q plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in the Private Placement, as set forth in the Form 8-K.

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Polaris Partners GP X, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 909,090.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 909,090.00

11

Aggregate amount beneficially owned by each reporting person

909,090.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Consists of 909,090 shares of Common Stock held of record by PP X (as defined in Item 2(a) of the Original Schedule 13D). PPGP X (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of PP X and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of Ms. Schulman and Mr. Chee (both as defined in Item 2(a) of the Original Schedule 13D) are the managing members of PPGP X. Mr. Nashat, a member of the Issuer's board of directors, holds an interest in PPGP X. Each of the PPGP X Managing Members (as defined in Item 2(a) of the Original Schedule 13D) and Mr. Nashat may be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 46,878,487 shares of Common Stock, which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as set forth in the Form 10-Q plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in the Private Placement, as set forth in the Form 8-K.

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Polaris Partners X, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 909,090.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 909,090.00

11

Aggregate amount beneficially owned by each reporting person

909,090.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All shares of Common Stock are held of record by PP X. PPGP X is the general partner of PP X. The PPGP X Managing Members are the managing members of PPGP X. Mr. Nashat, a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of the PPGP X Managing Members and Mr. Nashat may be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 46,878,487 shares of Common Stock, which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as set forth in the Form 10-Q plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in the Private Placement, as set forth in the Form 8-K.

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Amir Nashat

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,932,251.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,932,251.00

11

Aggregate amount beneficially owned by each reporting person

3,932,251.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Consists of (i) 2,825,500 shares of Common Stock held of record by PP VII, (ii) 197,661 shares of Common Stock held of record by PEF VII, and (iii) 909,090 shares of Common Stock held of record by PP X. PMC VII is the general partner of each of PP VII and PEF VII and may be deemed to have voting, investment and dispositive power with respect to these securities. The PMC VII Managing Members, including Mr. Nashat who is a member of the Issuer's board of directors, are the managing members of PMC VII and may be deemed to share voting, investment and dispositive power with respect to these securities. PPGP X is the general partner of PP X. The PPGP X Managing Members are the managing members of PPGP X. Mr. Nashat, a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of the PPGP X Managing Members and Mr. Nashat may be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 46,878,487 shares of Common Stock, which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as set forth in the Form 10-Q plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in the Private Placement, as set forth in the Form 8-K.

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Brian Chee

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 909,090.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 909,090.00

11

Aggregate amount beneficially owned by each reporting person

909,090.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

All shares of Common Stock are held of record by PP X. PPGP X is the general partner of PP X. The PPGP X Managing Members are the managing members of PPGP X. Mr. Nashat, a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of the PPGP X Managing Members and Mr. Nashat may be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 46,878,487 shares of Common Stock, which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as set forth in the Form 10-Q plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in the Private Placement, as set forth in the Form 8-K.

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Amy Schulman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 909,090.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 909,090.00

11

Aggregate amount beneficially owned by each reporting person

909,090.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.9 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

All shares of Common Stock are held of record by PP X. PPGP X is the general partner of PP X. The PPGP X Managing Members are the managing members of PPGP X. Mr. Nashat, a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of the PPGP X Managing Members and Mr. Nashat may be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 46,878,487 shares of Common Stock, which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as set forth in the Form 10-Q plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in the Private Placement, as set forth in the Form 8-K.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Camp4 Therapeutics Corporation
(c)	Address of Issuer's Principal Executive Offices: One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MASSACHUSETTS , 02139.
Item 1 Comment: This Amendment No. 1 (this "Amendment") amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on October 22, 2024 (the "Original Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original Schdule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.
Item 4.	Purpose of Transaction
	Solely on behalf of, and only to the extent that it relates to, the Reporting Persons, Item 4 of the Original Schedule 13D is hereby amended and supplemented by the addition of the following: The Reporting Persons have previously reserved the right and continue to reserve the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional shares of Common Stock or other securities of the Issuer, dispose of some or all of the shares of Common Stock or other securities of the Issuer that it may own from time to time, in each case in open market or private transactions, block sales or otherwise or pursuant to ordinary stock exchange transactions effected through one or more broker-dealers whether individually or utilizing specific pricing or other instructions (including by means of Rule 10b5-1 programs), and review or reconsider their position, change their purpose, take other actions or formulate and implement plans or proposals with respect to any of the foregoing. The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments.
Item 5.	Interest in Securities of the Issuer
(a)	See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person and the corresponding comments.
(b)	See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person and the corresponding comments.
(c)	On September 11, 2025, PP VII purchased 1,221,721 shares of Common Stock in connection with the Private Placement for $1.53 per share for an aggregate purchase amount of $1,869,233.13. On September 11, 2025, PEF VII purchased 85,468 shares of Common Stock in connection with the Private Placement for $1.53 per share for an aggregate purchase amount of $130,766.04.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	On September 9, 2025, the Issuer entered into a Securities Purchase Agreement (the "Purchase Agreement") with PP VII, PEF VII and certain other investors (each, an "Investor" and collectively, the "Investors"), pursuant to which the Issuer agreed to sell to the Investors, in up to two closings in the Private Placement. The initial closing of the Private Placement is anticipated to occur on or about September 11, 2025 (the "Initial Closing"), subject to customary closing conditions. At the Initial Closing, the Issuer has agreed to issue and sell 26,681,053 shares of Common Stock, at an offering price of $1.53 per share (the "Share Price") and, in lieu of Common Stock to certain Investors, pre-funded warrants to purchase 6,003,758 shares of Common Stock (the "Warrant Shares" and, together with the Common Stock, the "Securities") at an offering price of $1.5299 per pre-funded warrant (the "Pre-Funded Warrant Price"). At the Initial Closing, the Issuer will issue and sell to certain members of management, including the Issuer's CEO Josh Mandel-Brehm, the Issuer's CFO Kelly Gold, the Issuer's CMO Yuri Maricich, and the Issuer's co-founders Richard Young, who also serves as a director on the Issuer's Board of Directors (the "Board") and Leonard Zon, who serves as a Board observer, an additional 36,361 shares of Common Stock at a purchase price of $1.65 per share, for gross proceeds to the Issuer of approximately $50.1 million, before deducting placement agent fees and other expenses. Pursuant to the Purchase Agreement, subject to the occurrence of the Second Closing Trigger (defined below), the Investors have agreed to purchase at a closing (the "Second Closing") up to 32,721,172 shares of Common Stock or pre-funded warrants in lieu thereof at a purchase price per share and pre-funded warrant equal to the Share Price and the Pre-Funded Warrant Price, respectively, and members of management have agreed to an additional 39,306 shares of Common Stock at a purchase price of $1.65 per share, for gross proceeds to the Issuer of up to approximately $50.1 million. The Second Closing Trigger shall occur upon (i) the achievement of the first acceptance or clearance by a drug regulatory agency of a clinical trial application or similar filing submitted by the Issuer to commence a clinical trial in human subjects involving the administration of the Issuer's development candidate for the treatment of SYNGAP1-related disorders, or the time at which the Issuer is otherwise authorized under applicable law in such country or jurisdiction to commence such clinical trial (the "CTA Milestone"), and (ii) either (a) the achievement of a volume weighted average price per share of equal to or greater than $7.50 (subject to appropriate, proportional adjustment for any stock splits or combinations of the Common Stock occurring after the date of the Purchase Agreement) measured during any 10 consecutive trading days during the 30 trading days following the date of the Issuer's first announcement via a press release or Current Report on Form 8-K of the occurrence of the CTA Milestone (such period the "Measurement Period" and such price threshold requirement, the "Price Threshold") or (b) the Issuer's receipt of a written notice signed by the Investors holding a majority of the Securities outstanding from time to time and delivered to the Issuer during the Measurement Period that waives the Price Threshold for purposes of the Second Closing (the achievement or occurrence of (i) and (ii) are collectively, the "Second Closing Trigger"). In the event the Milestone Closing Trigger occurs as a result of a Price Threshold Waiver, only the waiving Investors will be obligated to purchase shares of Common Stock or pre-funded warrants at the Second Closing. The terms and conditions of the Private Placement are described in the Purchase Agreement, and the above summary is qualified by reference to such description and the full text of the Purchase Agreement, which is filed as Exhibit 7 to this Amendment and incorporated herein by reference. In connection with the Private Placement, the Investors entered into a Registration Rights Agreement, dated September 9, 2025, with the Issuer (the "Rights Agreement"). Pursuant to and subject to the terms of the Rights Agreement, the Issuer agreed to prepare and file to register for reseale the shares of Common Stock and the Warrant Shares underlying the pre-funded warrants issued pursuant to the Purchase Agreement. The terms and provisions of the Rights Agreement are described more fully in the Rights Agreement, and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 8 to this Amendment and is incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 7: Securities Purchase Agreement, dated September 9, 2025 (filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K as filed with the Commission on September 10, 2025 (SEC File No. 001-42365) and incorporated herein by reference). Exhibit 8: Registration Rights Agreement, dated September 9, 2025 (filed as Exhibit 10.2 to the Issuer's Current Report on Form 8-K as filed with the Commission on September 10, 2025 (SEC File No. 001-42365) and incorporated herein by reference).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Polaris Management Co. VII, L.L.C.

Signature:	/s/ Lauren Crockett
Name/Title:	Lauren Crockett, Attorney-in-Fact
Date:	09/11/2025

Polaris Partners VII, L.P.

Signature:	/s/ Lauren Crockett
Name/Title:	Lauren Crockett, Attorney-in-Fact for Polaris Management Co. VII, L.L.C. the general partner of Polaris Partners VII, L.P.
Date:	09/11/2025

Polaris Entrepreneurs' Fund VII, L.P.

Signature:	/s/ Lauren Crockett
Name/Title:	Lauren Crockett, Attorney-in-Fact for Polaris Management Co. VII, L.L.C. the general partner of Polaris Entrepreneurs' Fund VII, L.P.
Date:	09/11/2025

Polaris Partners GP X, L.L.C.

Signature:	/s/ Lauren Crockett
Name/Title:	Lauren Crockett, General Counsel
Date:	09/11/2025

Polaris Partners X, L.P.

Signature:	/s/ Lauren Crockett
Name/Title:	Lauren Crockett, General Counsel of Polaris Partners GP X, L.L.C. general partner of Polaris Partners X, L.P.
Date:	09/11/2025

Amir Nashat

Signature:	/s/ Lauren Crockett
Name/Title:	Lauren Crockett, Authorized Signatory
Date:	09/11/2025

Brian Chee

Signature:	/s/ Lauren Crockett
Name/Title:	Lauren Crockett, Authorized Signatory
Date:	09/11/2025

Amy Schulman

Signature:	/s/ Lauren Crockett
Name/Title:	Lauren Crockett, Authorized Signatory
Date:	09/11/2025

Comments accompanying signature:

This Amendment was executed with respect to each of Amir Nashat, Brian Chee, and Amy Schulman pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.

FAQ

What did the Schedule 13D/A for CAMP disclose about recent purchases?

It discloses that PP VII purchased 1,221,721 shares and PEF VII purchased 85,468 shares in the Private Placement on September 11, 2025, at $1.53 per share.

How much immediate capital will Camp4 receive from the Initial Closing?

The Initial Closing is expected to produce approximately $50.1 million of gross proceeds before placement agent fees and expenses.

What can trigger the Second Closing in the Purchase Agreement?

The Second Closing requires (i) a CTA milestone (first regulatory acceptance/clearance to start a clinical trial for the SYNGAP1 program) and (ii) either a $7.50 VWAP measured over any 10 consecutive trading days during a 30-trading-day Measurement Period or a written waiver by investors holding a majority of outstanding Securities.

Does the filing address resale of the issued shares?

Yes. Investors and the issuer entered into a Registration Rights Agreement under which the issuer agreed to prepare and file registration statements to enable resale of the issued Common Stock and underlying Warrant Shares.

How large are the Polaris-related holdings after these purchases?

Reported holdings include Polaris Management Co. VII: 3,023,161 shares (6.4%), Polaris Partners VII: 2,825,500 shares (6.0%), and Amir Nashat: 3,932,251 shares (8.4%), based on a 46,878,487 pro forma share base stated in the filing.